Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

86.67 +2.06 (+2.43%)
Streaming Delayed Price Updated: 1:43 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
22 23 Next >
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
From Incyte Corporation
Via Business Wire
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
From Incyte
Via Business Wire
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth. 
Via InvestorPlace
NASDAQ:INCY stands out as a stock that provides good value for the fundamentals it showcases.
INCYTE CORP (NASDAQ:INCY): good value for what you're paying. 
Via Chartmill
The Analyst Verdict: Incyte In The Eyes Of 8 Experts
 
Via Benzinga
NASDAQ:INCY is not too expensive for the growth it is showing.
INCYTE CORP (NASDAQ:INCY) is not too expensive for the growth it is showing. 
Via Chartmill
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
From Incyte
Via Business Wire
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
From Incyte
Via Business Wire
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off. 
Via InvestorPlace
NASDAQ:INCY stands out as a growth opportunity that won't break the bank.
For those who appreciate growth without the sticker shock, INCYTE CORP (NASDAQ:INCY) is worth considering. 
Via Chartmill
Exit Now! 3 Biotech Stocks to Sell in February 2024
These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability. 
Via InvestorPlace
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
From Incyte
Via Business Wire
Earnings Scheduled For February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. 
Via Benzinga
Despite its impressive fundamentals, NASDAQ:INCY remains undervalued.
INCYTE CORP (NASDAQ:INCY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Pancreatic Cancer Treatments Poised for Major Advances in 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B
Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat. 
Via Benzinga
Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion
Novartis will add to its cancer treatment pipeline with via the German biotech. 
Via Investor's Business Daily
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
From Incyte
Via Business Wire
Why Is MorphoSys (MOR) Stock Up 50% Today?
News of a potential takeout bid for any company usually leads to a big surge. That's what investors are seeing today with MOR stock. 
Via InvestorPlace
MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer
Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold... 
Via Benzinga
5 top healthcare stocks for earnings growth in 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed. 
Via MarketBeat
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
From Incyte
Via Business Wire
NASDAQ:INCY is probably undervalued for the fundamentals it is displaying.
For those who appreciate value investing, INCYTE CORP (NASDAQ:INCY) is a compelling option with its solid fundamentals. 
Via Chartmill
3 Pharma Stocks Could Be the Pills Your Portfolio Needs
These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations. 
Via InvestorPlace
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to  
Via Benzinga
In the world of growth stocks, NASDAQ:INCY shines as a value proposition.
Investors seeking growth at a reasonable cost should explore INCYTE CORP (NASDAQ:INCY). 
Via Chartmill
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
From Incyte
Via Business Wire
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
In a market where value is scarce, INCYTE CORP (NASDAQ:INCY) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.